Bipolar Disorder Drugs and Treatment Market Snapshot

The global market is expected to enjoy a valuation of US$ 4.4 Billion by the end of the year 2023, and further expand at a CAGR of 2.72% to reach a valuation of ~US$ 5.8 Billion by the year 2033. According to the recent study by Future Market Insights, anti- psychotic drugs are leading the market with an expected share of about 40.2% in the year 2023, within the global market.

Market Outlook

Data Points Market Insights
Market Value 2022 US$ 4.3 Billion
Market Value 2023 US$ 4.4 Billion
Market Value 2033 US$ 5.8 Billion
CAGR 2023 to 2033 2.72%
Market Share of Top 5 Countries 73.6%
Key Market Players AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC

Changing perspective about the importance of mental health treatments is anticipated to raise the sale of over the counter meds for bipolar disorder. According to the Global Burden of Disease report 2017, the prevalence of bipolar disorder ranges from 0.3% to 1.2% among different regions. In recent years, there has been growing awareness about the disorder, shifting the perspective for it as a mental ailment creating a surge in the sale of natural bipolar medication.

With the changing perspective about mental health, the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Bipolar Disorder Drugs and Treatment from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The market value for bipolar disorder drugs and treatment was approximately 20.3% of the overall ~US$ 21.2 Billion of the global psychotropic drugs market in 2022.

The sale of bipolar disorder drugs and treatment expanded at a CAGR of 2.10% from 2017 to 2022.

The market for bipolar disorder drugs and treatment was mildly hit by the COVID-19 pandemic restrictions. As there were widespread positive cases of patients infected by the novel coronavirus, most of the resources and professionals of the healthcare sector were diverted towards the management of the COVID-19 menace.

Particularly the demand for medication for bipolar from the hospital and healthcare institutions dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown. This fact is hypothesized from the information of the increase in the volume of over the counter medicine for bipolar available during the pandemic times. However, the market growth for prescribed drugs continued through the increase in online availability of bipolar meds on e-commerce sites.

As the healthcare sector was kept as the most prioritized business sector, the drugs market recovered from the jolt of the pandemic within a few days. There were also some remarkable developments in the field of herbal medicine for bipolar disorder that has emerged as a successful niche for the bipolar disorder drugs and treatment market.

Thus, owing to the aforementioned factors, the global bipolar disorder drugs and treatment market is expected to grow at a CAGR of 2.72% during the forecast period from 2023 to 2033.

H1-H2 Update

Market Statistics Details
Jan to Jun (H1), 2021 (A) 1.91%
Jul to Dec (H2), 2021 (A) 2.43%
Jan to Jun (H1),2022 Projected (P) 1.73%
Jan to Jun (H1),2022 Outlook (O) 1.86%
Jul to Dec (H2), 2022 Outlook (O) 2.68%
Jul to Dec (H2), 2022 Projected (P) 2.43%
Jan to Jun (H1), 2023 Projected (P) 2.12%
BPS Change : H1,2022 (O) - H1,2022 (P) 12↑
BPS Change : H1,2022 (O) - H1,2021 (A) (-) 6↓
BPS Change: H2, 2022 (O) - H2, 2022 (P) 25↑
BPS Change: H2, 2022 (O) - H2, 2021 (A) 25↑
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Key Opportunities for the Market Players?

Bipolar disorders have been recognized as the 6th largest contributor in the total disabled person in the world, by World Health Organizations or WHO. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that is available as over the counter meds in the drug stores.

Previously the consciousness and awareness about the remedial measures for any type of mental disorder were below the level, resulting in less demand for good medicine for bipolar disorder produced by the pharmaceutical companies. However, in recent days with the growth in digital media, the acceptance of methods for treatment of bipolar is reflected in the huge growth in sales of over the counter meds for bipolar cases.

There is also some old age natural medication for bipolar disorder that is being actively researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand values by supplying mood stabilizers online to customers.

What are the Factors Restraining Demand for Bipolar Disorder Drugs and Treatment?

The lithium (Li) element used in the production of anti-mania drugs can cause anorexia if taken by an overdose. Also, the prolonged use of lithium can damage the effects of vasopressin hormone that can result in diabetes insipid, as cited by many reports. This tact can hinder the wider adaptability of bipolar over the counter meds for disorder treatment as well.

As the typical age group for the emergence of any symptom of bipolar disorder is around 20 to 25 years, so it often gets neglected by the parents. This delays the tremendous procedure for bipolar disorders and reduces the effectiveness of natural bipolar meds, and hampers the value of the drug in the market. Over the years, a lot of generic medicines have been coming into the market competing with the well-established market chains of OTC mood stabilizer medications.

Addiction of the body to such types of drugs is another major concern for the use of bipolar treatment drugs by the patients. There is also very less number of anticonvulsant drugs approved for use as bipolar disorder medication over the counter that can hamper the rapid growth of the global market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

Country USA
2023 52.90%
2033 54.20%
BPS 129
Country Germany
2023 6.90%
2033 6.90%
BPS (-) 2
Country United kingdom
2023 5.30%
2033 5.40%
BPS 9
Country Brazil
2023 4.40%
2033 4.40%
BPS 7
Country France
2023 4.10%
2033 4.10%
BPS 5

What Makes the USA. a Large Market for Bipolar Disorder Drugs and Treatment?

The USA is set to obtain a share of around 52.90% in the global market, in 2023.

National Institute of Mental Health (NIMH) provides data for the number of people in USA developing bipolar disorder symptoms at approximately 10 million. By the support of government initiatives and dissemination of knowledge about the mental condition of such patients, there has been an encouraging environment for their treatment through proper medication for bipolar disorder.

The increase in disruption of daily lifestyle like insufficient sleep, wrong food habits or substance abuse and higher stress level in the youngster is the reason for the increasing sale of mood stabilizer medications over the counter, particularly in the USA.

What is the Outlook of Germany in the Bipolar Disorder Drugs and Treatment Market?

Germany is set to hold a market share of nearly 6.90% in the global bipolar disorder drugs and treatment market in 2023.

Strong policies to regulate the sale of over the counter medication for bipolar disorder is expected to enhance the growth of bipolar disorder drugs and the treatment market in this region.

How is the Market Expected to Grow in China?

China is set to expand at a CAGR of 2.50% in the global market, over the forecast period.

A rising frequency of mental diseases, greater awareness of bipolar disorders, and higher investments by major firms are all contributing to China's expected position as the market with the highest growth. A high patient population and rising public awareness of mental health issues have driven the market in the nation.

Category-wise Insights

Which Drug Class is Driving Market Growth?

Anti-psychotic drugs segment leads the market and is expected to hold a share of around 40.23% globally, in 2023.

Since they were first introduced into psychiatric therapy, antipsychotic drugs have been used to treat acute episodes of bipolar disease and prevent relapses. With the release of second-generation antipsychotic drugs, there has been a resurgence in interest in the ability of this class of drugs to treat manic-depression, which has increased the market share.

What Bipolar Disorder is Largely in Focus Globally?

Bipolar I disorder segment is set to hold a global market share of around 38.46% in 2023.

Manic episodes that continue at least seven days or manic symptoms severe enough to require emergency hospitalization are signs of bipolar I disorder. According to estimates from the National Institute of Mental Health (2020), 4.4% of American adults may experience bipolar illness at some point in their lifetime, which has sparked interest in the market segment globally.

Which Distribution Channel Benefits the Most Within the Global Market?

Hospital pharmacies is set to hold nearly half of the global a market share in 2023.

Growing rates of hospitalization as well as rising awareness on mental health globally has propelled the growth of this segment. Institutionalized patients have access to prescription drugs required for alleviation of disease symptoms, as well as for therapeutic purposes. Moreover, with access to adequate distribution networks, the segment is expected to gain traction over the forecast period, owed to greater accessibility of medications.

Competitive Landscape

The main strategies adopted by the market players include the development of new drugs for bipolar disorder over the counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over the counter medications is the most important step in gaining recognition for the newly developed medicines.

Expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.

  • For the treatment of bipolar I disorder among adults, Alkermes PLC developed a treatment drug by the name of LYBALVITM that is a combination of olanzapine and samidorphan. It received the approval of the US Food and Drug Administration (FDA) in June 2021, which will make it available as an over the counter medicine for bipolar treatment.
  • The University of Illinois, which is present in the state of Chicago, launched a cell phone app by the name of BiAffect in 2018 that helps in tracking the manic disorder and depressive mood for the patients having bipolar disorder.
  • Allergan PLC and Gedeon Richter PLC expanded the use of Vraylar, also known as cariprazine used in the treatment of the depressive condition in adults suffering from bipolar disorder after getting approval from the USA Food and Drug Administration (FDA) by May 2019.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the bipolar disorder drugs and treatment space, which are available in the full report.

Report Scope as per Bipolar Disorder Drugs and Treatment Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis US$ Mn for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, United kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa
Key Market Segments Covered Drug Class, Bipolar Disorder, Distribution Channel, and Region
Key Companies Profiled
  • AbbVie Inc.
  • Glaxo SmithKline (GSK)
  • ELI Lilly and Company
  • Janssen Pharmaceuticals
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Gedeon Richter Plc.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd
  • Validus Pharmaceuticals LLC
Pricing Available upon Request

Key Market Segments Covered in Bipolar Disorder Drugs and Treatment Industry Research

Drug Class:

  • Mood Stabilizer
  • Anticonvulsants
  • Anti-Psychotic Drugs
  • Anti-Depressant Drugs
  • Anti-Anxiety Drugs

Bipolar Disorder:

  • Bipolar I Disorder
  • Bipolar Ii Disorder
  • Cyclothymic Disorder

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

What magnitude will the market be in 2023?

In 2023, the market is expected to attain US$ 4.4 billion.

How big will the market be in 2033?

The sales are to spur to US$ 5.8 billion in 2033.

What is the market's growth's CAGR?

Through 2033, the market is set to evolve at a CAGR of 2.72%.

What was the CAGR of the market?

From 2018 to 2022, the global market advanced at a CAGR of 2.1%.

What is the status of the United States market?

In 2023, the United States is expected to possess a global market share of 52.90%.

What are the market forecasts for Germany?

In 2023, Germany is anticipated to have a 6.90% market share globally.

Table of Content
1. Executive Summary | Bipolar Disorder Drugs and Treatment Market
    1.1. Global Market Outlook
    1.2. Demand Side Trends
    1.3. Supply Side Trends
    1.4. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
    2.3. Inclusions and Exclusions
3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Market Innovation / Development Trends
4. Key Success Factors
    4.1. Disease Epidemiology, by Region
    4.2. Product Adoption / Usage Analysis
    4.3. Pipeline Assessment
    4.4. Regulatory Landscape
    4.5. Reimbursement Scenario
    4.6. PESTEL Analysis
    4.7. Porter’s Analysis
5. Market Background
    5.1. Macro-Economic Factors
        5.1.1. Global GDP Growth Outlook
        5.1.2. Global Healthcare Outlook
        5.1.3. Global Psychotropic Drugs Market Overview
    5.2. Forecast Factors - Relevance & Impact
        5.2.1. Rising Awareness on Mental Health Care
        5.2.2. Increasing Government Support for Psychiatric Disorders
        5.2.3. High Prevalence of Neurological and Neuropsychiatric Disorders
        5.2.4. Regulatory Scenario
        5.2.5. Reimbursement Considerations
        5.2.6. Cost of Treatment Regime
        5.2.7. Concerns with Addition from Treatment Drugs
    5.3. Market Dynamics
        5.3.1. Drivers
        5.3.2. Restraints
        5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
    6.1. COVID-19 and Impact Analysis
        6.1.1. By Drug Class
        6.1.2. By Bipolar Disorder
        6.1.3. By Distribution Channel
        6.1.4. By Country
    6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
    7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
    7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        7.2.1. Y-o-Y Growth Trend Analysis
        7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
        8.3.1. Mood Stabilizer
        8.3.2. Anticonvulsants
        8.3.3. Anti-Psychotic Drugs
        8.3.4. Anti-Depressant Drugs
        8.3.5. Anti-Anxiety Drugs
    8.4. Market Attractiveness Analysis By Drug Class
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Bipolar Disorder
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Million) Analysis, By Bipolar Disorder, 2017 to 2022
    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Bipolar Disorder, 2023 to 2033
        9.3.1. Bipolar I Disorder
        9.3.2. Bipolar Ii Disorder
        9.3.3. Cyclothymic Disorder
    9.4. Market Attractiveness Analysis By Bipolar Disorder
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
        10.3.1. Hospital Pharmacies
        10.3.2. Retail Pharmacies
        10.3.3. Online Pharmacies
    10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
    11.1. Introduction
    11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
        11.3.1. North America
        11.3.2. Latin America
        11.3.3. Europe
        11.3.4. East Asia
        11.3.5. South Asia
        11.3.6. Oceania
        11.3.7. Middle East and Africa (MEA)
    11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    12.1. Introduction
    12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        12.3.1. By Country
            12.3.1.1. USA
            12.3.1.2. Canada
        12.3.2. By Drug Class
        12.3.3. By Bipolar Disorder
        12.3.4. By Distribution Channel
    12.4. Market Attractiveness Analysis
        12.4.1. By Country
        12.4.2. By Drug Class
        12.4.3. By Bipolar Disorder
        12.4.4. By Distribution Channel
    12.5. Market Trends
    12.6. Key Market Participants - Intensity Mapping
    12.7. Drivers and Restraints - Impact Analysis
    12.8. Country Level Analysis & Forecast
        12.8.1. USA Market Analysis
            12.8.1.1. .Introduction
            12.8.1.2. Market Analysis and Forecast by Market Taxonomy
                12.8.1.2.1. By Drug Class
                12.8.1.2.2. By Bipolar Disorder
                12.8.1.2.3. By Distribution Channel
        12.8.2. Canada Market Analysis
            12.8.2.1. Introduction
            12.8.2.2. Market Analysis and Forecast by Market Taxonomy
                12.8.2.2.1. By Drug Class
                12.8.2.2.2. By Bipolar Disorder
                12.8.2.2.3. By Distribution Channel
13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    13.1. Introduction
    13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        13.3.1. By Country
            13.3.1.1. Mexico
            13.3.1.2. Brazil
            13.3.1.3. Argentina
            13.3.1.4. Rest of Latin America
        13.3.2. By Drug Class
        13.3.3. By Bipolar Disorder
        13.3.4. By Distribution Channel
    13.4. Market Attractiveness Analysis
        13.4.1. By Country
        13.4.2. By Drug Class
        13.4.3. By Bipolar Disorder
        13.4.4. By Distribution Channel
    13.5. Market Trends
    13.6. Key Market Participants - Intensity Mapping
    13.7. Drivers and Restraints - Impact Analysis
    13.8. Country Level Analysis & Forecast
        13.8.1. Mexico Market Analysis
            13.8.1.1. Introduction
            13.8.1.2. Market Analysis and Forecast by Market Taxonomy
                13.8.1.2.1. By Drug Class
                13.8.1.2.2. By Bipolar Disorder
                13.8.1.2.3. By Distribution Channel
        13.8.2. Brazil Market Analysis
            13.8.2.1. Introduction
            13.8.2.2. Market Analysis and Forecast by Market Taxonomy
                13.8.2.2.1. By Drug Class
                13.8.2.2.2. By Bipolar Disorder
                13.8.2.2.3. By Distribution Channel
        13.8.3. Argentina Market Analysis
            13.8.3.1. Introduction
            13.8.3.2. Market Analysis and Forecast by Market Taxonomy
                13.8.3.2.1. By Drug Class
                13.8.3.2.2. By Bipolar Disorder
                13.8.3.2.3. By Distribution Channel
14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    14.1. Introduction
    14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        14.3.1. By Country
            14.3.1.1. Germany
            14.3.1.2. Italy
            14.3.1.3. France
            14.3.1.4. United kingdom
            14.3.1.5. Spain
            14.3.1.6. BENELUX
            14.3.1.7. Russia
            14.3.1.8. Rest of Europe
        14.3.2. By Drug Class
        14.3.3. By Bipolar Disorder
        14.3.4. By Distribution Channel
    14.4. Market Attractiveness Analysis
        14.4.1. By Country
        14.4.2. By Drug Class
        14.4.3. By Bipolar Disorder
        14.4.4. By Distribution Channel
    14.5. Market Trends
    14.6. Key Market Participants - Intensity Mapping
    14.7. Drivers and Restraints - Impact Analysis
    14.8. Country Level Analysis & Forecast
        14.8.1. Germany Market Analysis
            14.8.1.1. Introduction
            14.8.1.2. Market Analysis and Forecast by Market Taxonomy
                14.8.1.2.1. By Drug Class
                14.8.1.2.2. By Bipolar Disorder
                14.8.1.2.3. By Distribution Channel
        14.8.2. Italy Market Analysis
            14.8.2.1. Introduction
            14.8.2.2. Market Analysis and Forecast by Market Taxonomy
                14.8.2.2.1. B By Drug Class
                14.8.2.2.2. By Bipolar Disorder
                14.8.2.2.3. By Distribution Channel
        14.8.3. France Market Analysis
            14.8.3.1. Introduction
            14.8.3.2. Market Analysis and Forecast by Market Taxonomy
                14.8.3.2.1. By Drug Class
                14.8.3.2.2. By Bipolar Disorder
                14.8.3.2.3. By Distribution Channel
        14.8.4. United kingdom Market Analysis
            14.8.4.1. Introduction
            14.8.4.2. Market Analysis and Forecast by Market Taxonomy
                14.8.4.2.1. By Drug Class
                14.8.4.2.2. By Bipolar Disorder
                14.8.4.2.3. By Distribution Channel
        14.8.5. Spain Market Analysis
            14.8.5.1. Introduction
            14.8.5.2. Market Analysis and Forecast by Market Taxonomy
                14.8.5.2.1. By Drug Class
                14.8.5.2.2. By Bipolar Disorder
                14.8.5.2.3. By Distribution Channel
        14.8.6. BENELUX Market Analysis
            14.8.6.1. Introduction
            14.8.6.2. Market Analysis and Forecast by Market Taxonomy
                14.8.6.2.1. By Drug Class
                14.8.6.2.2. By Bipolar Disorder
                14.8.6.2.3. By Distribution Channel
        14.8.7. Russia Market Analysis
            14.8.7.1. Introduction
            14.8.7.2. Market Analysis and Forecast by Market Taxonomy
                14.8.7.2.1. By Drug Class
                14.8.7.2.2. By Bipolar Disorder
                14.8.7.2.3. By Distribution Channel
15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    15.1. Introduction
    15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        15.3.1. By Country
            15.3.1.1. China
            15.3.1.2. Japan
            15.3.1.3. South Korea
        15.3.2. By Drug Class
        15.3.3. By Bipolar Disorder
        15.3.4. By Distribution Channel
    15.4. Market Attractiveness Analysis
        15.4.1. By Country
        15.4.2. By Drug Class
        15.4.3. By Bipolar Disorder
        15.4.4. By Distribution Channel
    15.5. Market Trends
    15.6. Key Market Participants - Intensity Mapping
    15.7. Drivers and Restraints - Impact Analysis
    15.8. Country Level Analysis & Forecast
        15.8.1. China Market Analysis
            15.8.1.1. Introduction
            15.8.1.2. Market Analysis and Forecast by Market Taxonomy
                15.8.1.2.1. By Drug Class
                15.8.1.2.2. By Bipolar Disorder
                15.8.1.2.3. By Distribution Channel
        15.8.2. Japan Market Analysis
            15.8.2.1. Introduction
            15.8.2.2. Market Analysis and Forecast by Market Taxonomy
                15.8.2.2.1. By Drug Class
                15.8.2.2.2. By Bipolar Disorder
                15.8.2.2.3. By Distribution Channel
        15.8.3. South Korea Market Analysis
            15.8.3.1. Introduction
            15.8.3.2. Market Analysis and Forecast by Market Taxonomy
                15.8.3.2.1. By Drug Class
                15.8.3.2.2. By Bipolar Disorder
                15.8.3.2.3. By Distribution Channel
16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    16.1. Introduction
    16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        16.3.1. By Country
            16.3.1.1. India
            16.3.1.2. Indonesia
            16.3.1.3. Malaysia
            16.3.1.4. Thailand
            16.3.1.5. Rest of South Asia
        16.3.2. By Drug Class
        16.3.3. By Bipolar Disorder
        16.3.4. By Distribution Channel
    16.4. Market Attractiveness Analysis
        16.4.1. By Country
        16.4.2. By Drug Class
        16.4.3. By Bipolar Disorder
        16.4.4. By Distribution Channel
    16.5. Market Trends
    16.6. Key Market Participants - Intensity Mapping
    16.7. Drivers and Restraints - Impact Analysis
    16.8. Country Level Analysis & Forecast
        16.8.1. India Market Analysis
            16.8.1.1. Introduction
            16.8.1.2. Market Analysis and Forecast by Market Taxonomy
                16.8.1.2.1. By Drug Class
                16.8.1.2.2. By Bipolar Disorder
                16.8.1.2.3. By Distribution Channel
        16.8.2. Indonesia Market Analysis
            16.8.2.1. Introduction
            16.8.2.2. Market Analysis and Forecast by Market Taxonomy
                16.8.2.2.1. By Drug Class
                16.8.2.2.2. By Bipolar Disorder
                16.8.2.2.3. By Distribution Channel
        16.8.3. Malaysia Market Analysis
            16.8.3.1. Introduction
            16.8.3.2. Market Analysis and Forecast by Market Taxonomy
                16.8.3.2.1. By Drug Class
                16.8.3.2.2. By Bipolar Disorder
                16.8.3.2.3. By Distribution Channel
        16.8.4. Thailand Market Analysis
            16.8.4.1. Introduction
            16.8.4.2. Market Analysis and Forecast by Market Taxonomy
                16.8.4.2.1. By Drug Class
                16.8.4.2.2. By Bipolar Disorder
                16.8.4.2.3. By Distribution Channel
17. Oceania Market 2017-2022 and Forecast 2023-2033
    17.1. Introduction
    17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        17.3.1. By Country
            17.3.1.1. Australia
            17.3.1.2. New Zealand
        17.3.2. By Drug Class
        17.3.3. By Bipolar Disorder
        17.3.4. By Distribution Channel
    17.4. Market Attractiveness Analysis
        17.4.1. By Country
        17.4.2. By Drug Class
        17.4.3. By Bipolar Disorder
        17.4.4. By Distribution Channel
    17.5. Market Trends
    17.6. Key Market Participants - Intensity Mapping
    17.7. Drivers and Restraints - Impact Analysis
    17.8. Country Level Analysis & Forecast
        17.8.1. Australia Market Analysis
            17.8.1.1. Introduction
            17.8.1.2. Market Analysis and Forecast by Market Taxonomy
                17.8.1.2.1. By Drug Class
                17.8.1.2.2. By Bipolar Disorder
                17.8.1.2.3. By Distribution Channel
        17.8.2. New Zealand Market Analysis
            17.8.2.1. Introduction
            17.8.2.2. Market Analysis and Forecast by Market Taxonomy
                17.8.2.2.1. By Drug Class
                17.8.2.2.2. By Bipolar Disorder
                17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    18.1. Introduction
    18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
        18.3.1. By Country
            18.3.1.1. GCC Countries
            18.3.1.2. Türkiye
            18.3.1.3. North Africa
            18.3.1.4. South Africa
            18.3.1.5. Rest of Middle East and Africa
        18.3.2. By Drug Class
        18.3.3. By Bipolar Disorder
        18.3.4. By Distribution Channel
    18.4. Market Attractiveness Analysis
        18.4.1. By Country
        18.4.2. By Drug Class
        18.4.3. By Bipolar Disorder
        18.4.4. By Distribution Channel
    18.5. Market Trends
    18.6. Key Market Participants - Intensity Mapping
    18.7. Drivers and Restraints - Impact Analysis
    18.8. Country Level Analysis & Forecast
        18.8.1. GCC Countries Market Analysis
            18.8.1.1. Introduction
            18.8.1.2. Market Analysis and Forecast by Market Taxonomy
                18.8.1.2.1. By Drug Class
                18.8.1.2.2. By Bipolar Disorder
                18.8.1.2.3. By Distribution Channel
        18.8.2. Türkiye Market Analysis
            18.8.2.1. Introduction
            18.8.2.2. Market Analysis and Forecast by Market Taxonomy
                18.8.2.2.1. By Drug Class
                18.8.2.2.2. By Bipolar Disorder
                18.8.2.2.3. By Distribution Channel
        18.8.3. South Africa Market Analysis
            18.8.3.1. Introduction
            18.8.3.2. Market Analysis and Forecast by Market Taxonomy
                18.8.3.2.1. By Drug Class
                18.8.3.2.2. By Bipolar Disorder
                18.8.3.2.3. By Distribution Channel
        18.8.4. North Africa Market Analysis
            18.8.4.1. Introduction
            18.8.4.2. Market Analysis and Forecast by Market Taxonomy
                18.8.4.2.1. By Drug Class
                18.8.4.2.2. By Bipolar Disorder
                18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
    19.1. Market Analysis by Tier of Companies
    19.2. Market Share Analysis of Top Players
    19.3. Market Presence Analysis
20. Competition Analysis
    20.1. Competition Dashboard
    20.2. Competition Benchmarking
    20.3. Competition Deep Dive
        20.3.1. AbbVie Inc.
            20.3.1.1. Overview
            20.3.1.2. Product Portfolio
            20.3.1.3. Sales Footprint
            20.3.1.4. Key Financials
            20.3.1.5. SWOT Analysis
            20.3.1.6. Strategy Overview
                20.3.1.6.1. Marketing Strategy
                20.3.1.6.2. Product Strategy
                20.3.1.6.3. Channel Strategy
        20.3.2. Glaxo SmithKline (GSK)
        20.3.3. ELI Lilly and Company
        20.3.4. Janssen Pharmaceuticals
        20.3.5. Astellas Pharma Inc.
        20.3.6. Bristol Myers Squibb
        20.3.7. Gedeon Richter Plc.
        20.3.8. H. Lundbeck A/S
        20.3.9. Pfizer Inc.
        20.3.10. Novartis AG
        20.3.11. Otsuka Holdings Co. Ltd
        20.3.12. Validus Pharmaceuticals LLC
21. Assumptions and Acronyms Used
22. Research Methodology
Recommendations

Healthcare

Psychotropic Drugs Market

October 2023

REP-GB-9134

306 pages

Healthcare

Anxiety Disorders And Depression Treatment Market

November 2022

REP-GB-15808

250 pages

Healthcare

Depression Treatment Market

May 2022

REP-GB-14687

443 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Bipolar Disorder Drugs and Treatment Market

Schedule a Call